Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
Altimmune, Inc. (NASDAQ: ALT), a Delaware corporation, filed this Current Report on Form 8-K on February 25, 2021. The filing reports the entry into a material definitive agreement to establish an at-the-market equity offering program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization to raise up to $125.0 million through the sale of common stock. The company will pay the sales agents a commission of 3.0% of the gross sales proceeds.
Material Changes
The material change reported is the execution of an Equity Distribution Agreement with Piper Sandler & Co., Evercore Group L.L.C., and B. Riley Securities, Inc. This agreement allows the company to sell shares of its common stock from time to time at its sole discretion through the sales agents. The shares will be issued pursuant to a Registration Statement on Form S-3 declared effective on January 11, 2021.
Outlook, Risks, and Management Commentary
The sales agents are not required to sell any specific number or dollar amount of securities but will use commercially reasonable efforts to sell shares requested by the company. There is no arrangement for funds to be held in escrow. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Key Facts for Investor Verification
- Authorization to sell up to $125.0 million in common stock via an at-the-market offering.
- Sales agents include Piper Sandler & Co., Evercore Group L.L.C., and B. Riley Securities, Inc.
- Commission rate of 3.0% on gross proceeds.
- Shares are issued under a Form S-3 registration statement effective January 11, 2021.
- No specific sales volume is guaranteed by the sales agents.